Cemiplimab monotherapy in advanced non-squamous and squamous non-small cell lung cancer

Affiliations

¹ Catalan Institute of Oncology, Laboratory of Cellular and Molecular Biology, Institute for Health Science Research Germans Trias i Pujol, 08916 Badalona, Spain; Universitat Autónoma de Barcelona, Barcelona, Spain; Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Dexeus University Hospital, Barcelona, Spain. Electronic address: rrosell@iconcologia.net.
² Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Dexeus University Hospital, Barcelona, Spain.

Comment

Rafael Rosell et al. Lancet. 2021.

. 2021 Feb 13;397(10274):557-559.

doi: 10.1016/S0140-6736(21)00196-3.

¹ Catalan Institute of Oncology, Laboratory of Cellular and Molecular Biology, Institute for Health Science Research Germans Trias i Pujol, 08916 Badalona, Spain; Universitat Autónoma de Barcelona, Barcelona, Spain; Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Dexeus University Hospital, Barcelona, Spain. Electronic address: rrosell@iconcologia.net.
² Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Dexeus University Hospital, Barcelona, Spain.

No abstract available

Comment on

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, Turk HM, Cicin I, Bentsion D, Gladkov O, Clingan P, Sriuranpong V, Rizvi N, Gao B, Li S, Lee S, McGuire K, Chen CI, Makharadze T, Paydas S, Nechaeva M, Seebach F, Weinreich DM, Yancopoulos GD, Gullo G, Lowy I, Rietschel P. Sezer A, et al. Lancet. 2021 Feb 13;397(10274):592-604. doi: 10.1016/S0140-6736(21)00228-2. Lancet. 2021. PMID: 33581821 Clinical Trial.